Loading…
Soligenix, Inc. is projected to decline to $0.3249 by 2027, a -10% move from its current price of $0.3599. SNGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.3385 | $0.3601 | $0.3832 | +0.07% |
| Jul 14 | $0.3301 | $0.3604 | $0.3935 | +0.14% |
| Jul 15 | $0.3238 | $0.3606 | $0.4016 | +0.20% |
| Jul 16 | $0.3187 | $0.3609 | $0.4086 | +0.27% |
| Jul 17 | $0.3143 | $0.3611 | $0.4149 | +0.34% |
| Jul 18 | $0.3104 | $0.3614 | $0.4207 | +0.41% |
| Jul 19 | $0.3068 | $0.3616 | $0.4262 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3068 | $0.3616 | $0.4262 | +0.47% |
| Week 2 | $0.288 | $0.3633 | $0.4584 | +0.95% |
| Week 3 | $0.2746 | $0.365 | $0.4852 | +1.43% |
| Week 4 | $0.264 | $0.3668 | $0.5095 | +1.91% |
| Week 5 | $0.2552 | $0.3685 | $0.5321 | +2.39% |
| Week 6 | $0.2476 | $0.3702 | $0.5537 | +2.87% |
| Week 7 | $0.2408 | $0.372 | $0.5746 | +3.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.
Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc.
in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Soligenix, Inc. (SNGX) is currently trading at $0.37. Its market capitalization is $5.48M and it ranks 5292. The price outlook is reflected in a year-by-year forecast that places the 2026 average at $0.37 and shows a path to higher targets later in the decade, including a 2030 average of $0.4787, a 2040 average of $0.8135, and a 2050 average of $1.16.
ROI figures accompany the forecast, with 2026 at 0, 2027 at -8.9, 2028 at 26.6, 2029 at 58.2, 2030 at 29.4, 2040 at 119.9, and 2050 at 213.2. The overall path suggests a transition from neutral to bullish sentiment in later years, though actual results will depend on market conditions and other factors.
A major floor 22.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 169.5% above — a clean break opens room to run.
A major ceiling 294.6% above — clearing it would confirm fresh momentum.
Key SNGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.374 | Sell | $0.3729 | Sell |
| MA 10 | $0.387 | Sell | $0.3839 | Sell |
| MA 20 | $0.3985 | Sell | $0.4112 | Sell |
| MA 50 | $0.4368 | Sell | $0.5353 | Sell |
| MA 100 | $0.8079 | Sell | $0.7549 | Sell |
| MA 200 | $1.12 | Sell | $1.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.26 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -154.15 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -5.26 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.34 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 20.95 | Buy |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.36 | Sell |
| ADX (14) | 21.82 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40, and the price action is trading near the 50-day and 200-day moving averages. The SMA50 is $0.459 and the SMA200 is $1.14. Support is listed at $0.37 and resistance at $0.97. The 30-day range spans from $0.2396 to $0.5713.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.28 | $0.3599 | $0.4786 | 0% | Neutral | |
| $0.2358 | $0.3249 | $0.4842 | -10% | Neutral | |
| $0.3063 | $0.4486 | $0.7124 | +25% | Bullish | |
| $0.3697 | $0.5704 | $0.9509 | +58% | Bullish | |
| $0.2872 | $0.4646 | $0.8062 | +29% | Bullish | |
| $0.2668 | $0.451 | $0.8103 | +25% | Bullish | |
| $0.2676 | $0.4718 | $0.874 | +31% | Bullish | |
| $0.2126 | $0.3904 | $0.7433 | +8% | Neutral | |
| $0.293 | $0.5596 | $1.09 | +56% | Bullish | |
| $0.3384 | $0.6718 | $1.34 | +87% | Bullish | |
| $0.3483 | $0.774 | $1.70 | +115% | Bullish | |
| $0.5085 | $1.13 | $2.60 | +214% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.28 | $0.3599 | $0.4653 | +0.00% |
| August 2026 | $0.3341 | $0.4046 | $0.5104 | +12.43% |
| September 2026 | $0.3116 | $0.3827 | $0.4929 | -5.41% |
| October 2026 | $0.2912 | $0.3621 | $0.4745 | -5.40% |
| November 2026 | $0.2951 | $0.3708 | $0.493 | +2.40% |
| December 2026 | $0.28 | $0.3553 | $0.4786 | -4.18% |
Click any year to see its month-by-month SNGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SNGX to range from $0.28 to $0.4786 through 2026. The $0.3599 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The SNGX price prediction for 2027 points to an average of $0.3249 (low $0.2358, high $0.4842) — a potential decline of -10% on today's $0.3599. Price action looks broadly range-bound.
In 2028, SNGX is projected to trade between $0.3063 and $0.7124, averaging $0.4486 — a potential gain of +25% from today's $0.3599. That is up +38% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Soligenix, Inc.'s 2029 outlook centres on $0.5704, within a $0.3697 to $0.9509 range. That is up +27% on the projected 2028 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2030, SNGX could reach as high as $0.8062, with a base case around $0.4646 and support toward $0.2872 — roughly +29% from $0.3599. Buyers look set to stay in control over this stretch.
Expect SNGX to range from $0.2668 to $0.8103 through 2031. The $0.451 average target implies a +25% move from current prices. That is -3% versus the projected 2030 average. Momentum favours further upside here.
The SNGX price prediction for 2032 points to an average of $0.4718 (low $0.2676, high $0.874) — a potential gain of +31% on today's $0.3599. Buyers look set to stay in control over this stretch.
In 2033, SNGX is projected to trade between $0.2126 and $0.7433, averaging $0.3904 — a potential gain of +8% from today's $0.3599. That is -17% versus the projected 2032 average. Price action looks broadly range-bound.
Soligenix, Inc.'s 2034 outlook centres on $0.5596, within a $0.293 to $1.09 range. That is up +43% on the projected 2033 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, SNGX could reach as high as $1.34, with a base case around $0.6718 and support toward $0.3384 — roughly +87% from $0.3599. Momentum favours further upside here.
Expect SNGX to range from $0.3483 to $1.70 through 2040. The $0.774 average target implies a +115% move from current prices. That is up +15% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The SNGX price prediction for 2050 points to an average of $1.13 (low $0.5085, high $2.60) — a potential gain of +214% on today's $0.3599. Momentum favours further upside here.
Investing $1,000 in SNGX today (≈ 2,778.549597 SNGX) could be worth
$3,139.86
+$2,139.86 (+214%) by 2050 · US Dollar
Based on the average projected SNGX price of $1.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNGXwould be worth at today's price.
$1,000 invested in SNGX on Jul 10, 2025 (≈ 787.401587 SNGX) would be worth
$283.39
-$716.61 (-71.7%) today · 0.28× · US Dollar
Based on a SNGX entry price of $1.27 vs. today's $0.3599.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.39 | $922.82 | -7.7% |
| 1 month ago | $0.46 | $782.39 | -21.8% |
| 3 months ago | $1.12 | $321.34 | -67.9% |
| 6 months ago | $1.37 | $262.7 | -73.7% |
| 1 year ago | $1.27 | $283.39 | -71.7% |
| All time (5.0y) ago | $244.8 | $1.47 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNGX forecast.
Our base-case forecast reaches $0.72 around 2040.
Implied market cap at $0.72: $10.67M
Forecasts show a multi-year trajectory with notable targets in the later years. The 2026 average is $0.37 with ROI 0 and NEUTRAL sentiment, while 2027 shows an average of $0.3371 with ROI -8.9 and NEUTRAL sentiment; 2028 is $0.4685 with ROI 26.6 and BULLISH. The 2029 forecast is $0.5855 (ROI 58.2, BULLISH), and 2030 is $0.4787 (ROI 29.4, BULLISH).
The 2034 and 2035 horizons continue higher, with 2034 at $0.5843 (ROI 57.9, BULLISH) and 2035 at $0.6949 (ROI 87.8, BULLISH). Longer horizon targets include 2040 at $0.8135 (ROI 119.9, BULLISH) and 2050 at $1.16 (ROI 213.2, BULLISH). These are estimates, not guarantees.
Tap a question to reveal the answer.
2030 — min $0.2959, avg $0.4787, max $0.8311; ROI 29.4; sentiment BULLISH.
Forecasts show 2027 ROI -8.9 with NEUTRAL sentiment; 2028 ROI 26.6, 2029 ROI 58.2, 2030 ROI 29.4, 2040 ROI 119.9, and 2050 ROI 213.2, with overall bullish long-term potential. These are estimates, not guarantees.
Yes, according to the forecast, max values include 2034 $1.14, 2035 $1.39, 2040 $1.79, and 2050 $2.67.
Current price is $0.37 and market capitalization is $5.48M.
Sentiment NEUTRAL; RSI14 40; SMA50 $0.459; SMA200 $1.14; support $0.37; resistance $0.97; 30-day range low $0.2396 and high $0.5713.
Soligenix, Inc. Community Discussion
0Share your Soligenix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.